SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Zelda Fitzgerald — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientZelda Fitzgerald
Date of birth1900-07-24
IdentifiersMRN HR-ET004-SYN-TD; SSN (made up) 000-04-8712
Document date1930-06-08
AuthorMargot Ellery, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Lithium level after the sick visit, prolactin, and the antipsychotic plan. [S]

History of Present Illness

Ms. Fitzgerald returns one week after the sick visit for gastroenteritis, when her lithium level was 1.4 mmol/L. She held lithium for two days as advised, was eating and drinking normally by the third day, and restarted 300 mg twice daily five days ago. The diarrhea stopped within four days. Her tremor is back to a faint shake when she is tired. She admits that she did not go for the lithium level that was due a week after starting, because she felt well and forgot. Her mood is better, and she has had no manic or psychotic symptoms. She saw the sports dietitian and is eating three meals and two snacks; she has started one gentle class a day. Her periods have not returned. She has had no thoughts of suicide or self-harm. [S]

ElementDetail
LithiumHeld two days, restarted five days ago at 300 mg twice daily
GastroenteritisResolved
MoodBetter; PHQ-9 7; item 9 scored 0
PeriodsStill absent
Food and danceThree meals and two snacks; one gentle class a day

Review of Systems

SystemResultFinding
GastrointestinalNegativeDiarrhea and vomiting resolved; eating normally
GenitourinaryPositiveNo periods; no increased urination
NeurologicalNegativeFaint tremor only when tired; no unsteadiness or confusion
PsychiatricNegativeMood better; no manic or psychotic symptoms; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital)One tablet by mouth at bedtimeOral route1930-04-20 to 1930-06-08completedS
Lithium carbonate 300 mg oral capsule, one capsule by mouth twice dailyOne capsule by mouth twice dailyOral route1930-05-18activeS
Risperidone 1 mg oral tablet, one tablet by mouth at bedtime for one week, then stopOne tablet by mouth at bedtime for one weekOral route1930-06-08 to 1930-06-15completedS
Aripiprazole 10 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route1930-06-08activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1930-06-08Body height165cmS
1930-06-08Body weight50.2kgS
1930-06-08Body mass index (BMI) [Ratio]18.4kg/m2S
1930-06-08Systolic blood pressure104mm[Hg]S
1930-06-08Diastolic blood pressure66mm[Hg]S
1930-06-08Heart rate74/minS
1930-06-08Respiratory rate14/minS
1930-06-08Body temperature36.6CelS
1930-06-08Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1930-06-08Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1930-06-08Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1930-06-08Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
1930-06-08Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M105mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1930-06-08Lithium [Moles/volume] in Serum or Plasma0.8mmol/LMaintenance target 0.6 to 0.8 mmol/L; above 1.2 mmol/L is above the therapeutic rangeNormalS
1930-06-08Prolactin [Mass/volume] in Serum or Plasma66ng/mL4.8-23.3 ng/mLHighS
1930-06-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S

Physical Exam

Vital signs recorded on 1930-06-08; see the Vital Signs section. [S]

SystemFinding
GeneralWell and well hydrated; weight 50.2 kg; blood pressure 104/66, pulse 74
NeurologicalVery faint fine postural tremor; no ataxia; no akathisia or rigidity
PsychiatricBrighter; organized; no psychotic or manic features

Problems

ProblemClinical statusVerificationCodeProvenance
First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalizationactiveprovisional F29S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit.
Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negativeactiveconfirmed N91.1S — Synthetic presenting finding linked to her documented training; resolved when her periods returned.
Acute viral gastroenteritis (vomiting and watery diarrhea for two days, roommate with the same illness), with mild dehydration; resolvedresolvedconfirmed A08.4S — Synthetic acute infection; not a historical claim.
Lithium level above the therapeutic range (1.4 mmol/L) during dehydration, with nausea and a worse fine tremor, without confusion or unsteadiness; lithium held and restarted; resolvedresolvedconfirmed T43.595AS — Synthetic medication adverse effect at a prescribed dose; ICD-10-CM classifies lithium salts with the other antipsychotics and neuroleptics.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyAntipsychotic dose, adherence, and responseEvery visitCompleted todayRisperidone 2 mg; switching to aripiprazole 10 mg with a one-week taper
SurveyManic, depressive, and psychotic symptoms, and early warning signsEvery visitCompleted todayNo manic, depressive-episode, or psychotic symptoms
ExaminationAkathisia, parkinsonism, and sedationEvery visit in the first months and after any dose changeCompleted todayNone; to be checked during the switch
ExaminationWeight and BMIEvery visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly)Completed today50.2 kg, down 0.8 kg after the gastroenteritis
LaboratoryProlactinWhen there are symptoms of high prolactin, such as missed periodsCompleted today66 ng/mL, still raised, with absent periods; antipsychotic switched
LaboratoryLithium level (12-hour trough)5 to 7 days after starting and after any change until stable, then every 3 to 6 monthsDeferredThe level due 5 to 7 days after starting was not drawn: she felt well and missed the laboratory visit. The first level was at the sick visit (1.4 mmol/L, raised by dehydration, not by the dose). Today 0.8 mmol/L, five days after restarting. Corrective action: the care coordinator sends a reminder before each laboratory test
LaboratoryCreatinine and eGFR on lithiumBaseline, every 2 to 3 months for 6 months, then every 6 to 12 monthsCompleted todayCreatinine 0.78 mg/dL, eGFR 105, back from 1.08 at the sick visit; sodium 139, potassium 4.1 mmol/L
LaboratoryTSH on lithiumBaseline, once or twice in the first 6 months, then every 6 to 12 monthsUp to dateBaseline normal; next at three months
Medication safetyLithium side effects and sick-day rulesAt the start and every visitCompleted todayFaint tremor only; sick-day plan in her phone
Medication safetyPregnancy prevention on lithium; valproate avoidedBefore starting and at each visit until a reliable method is in placeCompleted todayCondoms used; long-acting methods discussed; she will decide at the preventive visit
SurveyDepression measure (PHQ-9)Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodicallyCompleted todayPHQ-9 7, item 9 scored 0
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in her phone
Self-managementSleepEvery visitCompleted todayEight or nine hours
Self-managementEating, exercise, and periodsEvery visit while periods are absent or weight is lowCompleted todayDietitian plan of three meals and two snacks; one gentle class a day; periods absent
Self-managementCoordinated specialty care engagementOngoing, for up to two to three yearsCompleted todayCare coordinator weekly; therapist started

Goal progress:

Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Three-month visit in nine weeks, fasting, with lithium level, kidney and thyroid tests, calcium, prolactin, glucose, A1c, and lipids. Care coordinator weekly. Next scheduled visit 1930-08-10: three-month review: lithium, thyroid, kidney and metabolic checks, and the diagnosis reviewed. [S]